April 28, 2004
Steve Goldstein
CBS MarketWatch
Swiss biotech Serono (SRA) on Wednesday said a study said its Rebif drug can reduce the long-term accumulation of brain lesion volume in remitting multiple sclerosis drug. The study was presented at the annual American Academy of Neurology meeting.
Copyright © 2004, MarketWatch